Showing results (441-450 of 561) with videos related to
Sort By:
Pageof 57
Oncotarget|October 22, 2016
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trialMatthew D Hale, Matthew Nankivell, Gordon G Hutchins, et al.European Journal of Cancer (Oxford, England : 1990)|January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimensJonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.The Lancet. Oncology|April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.The Lancet. Haematology|April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trialMichael Northend, William Wilson, Kushani Ediriwickrema, et al.The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.The British Journal of Surgery|February 18, 2022
Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinomaArnaldo N S Silva, Yuichi Saito, Takaki Yoshikawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.Journal of the National Cancer Institute|August 21, 2014
Risk of premature menopause after treatment for Hodgkin's lymphomaAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.Pageof 57